# Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.

> **NCT02405910** · PHASE2 · WITHDRAWN · sponsor: **West Virginia University**

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02405910
- **Lead sponsor:** West Virginia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-03-15
- **Primary completion:** 2017-12
- **Final completion:** 2023-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI Left Institution
- **Last updated:** 2017-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02405910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02405910, "Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02405910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*